FAPI PET/CT provides higher uptake and better target to back ground in recurrent and metastatic tumors of patients with Iodine refractory papillary thyroid cancer compared with FDG PET CT
Nuklearmedizin - NuclearMedicine · 2025-06 · 64 (03) · 188-192
DOI: 10.1055/a-2185-7746 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Nuklearmedizin - NuclearMedicine, online erschienen am 08.01.2024. Verfasst von Shaghayegh Nourbakhsh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran, Iran. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Thyroid Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
The role of fibroblast activation protein inhibitor (FAPI) PET CT scan is not well documented in papillary thyroid cancer (PTC) patients. Patients with radioiodine refractory PTC and high thyroglobulin levels need PET/CT scan which is generally done by 18F FDG. In the current study, the diagnostic performance of 68Ga FAPI and FDG PET/CT scans were compared head to head in patients with radioiodine refractory PTC. Fourteen patients with negative whole body Iodine scans and high thyroglobulin levels underwent whole body PET scans with, respectively, 120–310 and 145–370 MBq 68Ga FAPI-46 and 18F FDG. SUVmax of the back ground in the blood pool and liver and the hottest, largest and average neck, mediastinum, lung and bone lesions were calculated and compared. Ten patients had at least one active (SUVmax>blood pool) lesion similarly in two scans. The liver and blood pool SUVmax values were 1.25(0.2) and 1.7(0.2) in FAPI and 2.65(0.2) and 2.0(0.2) in FDG PET images, respectively. The difference was significant (p=0.001). Standard SUV of the hottest lesion to liver was above 3 in all FAPI scans but in half of FDG scans. Target lesion number and intensity were similar between two PET studies but in a patient out of 5 pulmonary metastatic patients, pulmonary nodules were negative (SUVmax=0.9) in FDG while positive (SUVmax= 3.8) in FAPI images (i.e. 20% patient upstaged). FAPI accumulates in the recurrent and metastatic lesions of patients with Iodine refractory PTC at least as well as FDG with particular privileges as lower injected activity and lower back ground.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran, Iran.
- Department of Radiation oncology, Imam Khomeini Hospital Complex, Tehran, Iran.
Zitieren
APA
Nourbakhsh, S., Salehi, Y., Farzanehfar, S., Ghaletaki, R., Bakhshi Kashi, M., & Abbasi, M. (2025). FAPI PET/CT provides higher uptake and better target to back ground in recurrent and metastatic tumors of patients with Iodine refractory papillary thyroid cancer compared with FDG PET CT. Nuklearmedizin - NuclearMedicine, 64(03), 188-192. https://doi.org/10.1055/a-2185-7746
Vancouver
Nourbakhsh S, Salehi Y, Farzanehfar S, Ghaletaki R, Bakhshi Kashi M, Abbasi M. FAPI PET/CT provides higher uptake and better target to back ground in recurrent and metastatic tumors of patients with Iodine refractory papillary thyroid cancer compared with FDG PET CT. Nuklearmedizin - NuclearMedicine. 2025;64(03):188-192. doi:10.1055/a-2185-7746
BibTeX
@article{Nourbakhsh2025,
author = {Nourbakhsh, Shaghayegh and Salehi, Yalda and Farzanehfar, Saeed and Ghaletaki, Reza and Bakhshi Kashi, Mohsen and Abbasi, Mehrshad},
title = {FAPI PET/CT provides higher uptake and better target to back ground in recurrent and metastatic tumors of patients with Iodine refractory papillary thyroid cancer compared with FDG PET CT},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2025},
volume = {64},
number = {03},
pages = {188--192},
doi = {10.1055/a-2185-7746}
}
EUVIMED